Benjamin Bitler
Concepts (418)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 52 | 2026 | 599 | 13.910 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 16 | 2026 | 137 | 5.490 |
Why?
| | Cystadenocarcinoma, Serous | 9 | 2026 | 90 | 3.990 |
Why?
| | Claudin-4 | 5 | 2025 | 18 | 2.920 |
Why?
| | Genomic Instability | 3 | 2025 | 68 | 2.480 |
Why?
| | Drug Resistance, Neoplasm | 14 | 2026 | 889 | 2.470 |
Why?
| | Cell Line, Tumor | 45 | 2026 | 3565 | 2.410 |
Why?
| | Phthalazines | 6 | 2026 | 63 | 2.380 |
Why?
| | Histone-Lysine N-Methyltransferase | 4 | 2024 | 141 | 2.150 |
Why?
| | Tumor Microenvironment | 14 | 2026 | 748 | 2.080 |
Why?
| | Piperazines | 6 | 2026 | 375 | 2.060 |
Why?
| | Fallopian Tubes | 3 | 2024 | 33 | 1.630 |
Why?
| | Xenograft Model Antitumor Assays | 11 | 2026 | 939 | 1.570 |
Why?
| | Gene Expression Regulation, Neoplastic | 23 | 2026 | 1457 | 1.520 |
Why?
| | Nuclear Proteins | 10 | 2018 | 745 | 1.450 |
Why?
| | Transcription Factors | 13 | 2023 | 1747 | 1.360 |
Why?
| | Polycomb Repressive Complex 1 | 4 | 2026 | 66 | 1.220 |
Why?
| | Cellular Senescence | 8 | 2026 | 229 | 1.150 |
Why?
| | Antineoplastic Agents | 8 | 2026 | 2231 | 1.060 |
Why?
| | Poly(ADP-ribose) Polymerases | 4 | 2026 | 88 | 1.040 |
Why?
| | beta Catenin | 4 | 2025 | 254 | 1.020 |
Why?
| | Cell Proliferation | 13 | 2026 | 2529 | 0.990 |
Why?
| | Mice | 36 | 2026 | 18493 | 0.970 |
Why?
| | Tumor Escape | 2 | 2025 | 50 | 0.930 |
Why?
| | Female | 69 | 2026 | 80081 | 0.910 |
Why?
| | Immune Evasion | 1 | 2025 | 63 | 0.880 |
Why?
| | BRCA2 Protein | 5 | 2024 | 68 | 0.870 |
Why?
| | Tryptophan Oxygenase | 2 | 2024 | 33 | 0.860 |
Why?
| | Autophagy | 2 | 2024 | 291 | 0.860 |
Why?
| | Animals | 49 | 2026 | 38417 | 0.820 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2025 | 2001 | 0.790 |
Why?
| | Histocompatibility Antigens | 2 | 2024 | 102 | 0.790 |
Why?
| | Neoplasms | 6 | 2023 | 2946 | 0.750 |
Why?
| | Mucin-1 | 4 | 2012 | 29 | 0.750 |
Why?
| | Humans | 85 | 2026 | 147306 | 0.740 |
Why?
| | Wnt Signaling Pathway | 5 | 2025 | 212 | 0.730 |
Why?
| | Ovary | 2 | 2022 | 236 | 0.730 |
Why?
| | Indoles | 4 | 2025 | 510 | 0.710 |
Why?
| | Protein-Arginine N-Methyltransferases | 2 | 2019 | 25 | 0.700 |
Why?
| | DNA-Binding Proteins | 9 | 2020 | 1488 | 0.690 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 2 | 2021 | 27 | 0.690 |
Why?
| | Breast Neoplasms | 6 | 2024 | 2420 | 0.680 |
Why?
| | Mutation | 11 | 2026 | 4130 | 0.680 |
Why?
| | Neoplasms, Glandular and Epithelial | 4 | 2018 | 52 | 0.670 |
Why?
| | Ascites | 1 | 2021 | 48 | 0.650 |
Why?
| | Up-Regulation | 5 | 2020 | 848 | 0.640 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2022 | 268 | 0.640 |
Why?
| | ErbB Receptors | 5 | 2024 | 638 | 0.640 |
Why?
| | DNA Repair | 5 | 2026 | 256 | 0.630 |
Why?
| | Genomics | 2 | 2024 | 839 | 0.620 |
Why?
| | Epoxy Compounds | 1 | 2020 | 31 | 0.620 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2020 | 69 | 0.610 |
Why?
| | Endometrial Neoplasms | 4 | 2025 | 205 | 0.610 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2020 | 49 | 0.610 |
Why?
| | Rad51 Recombinase | 1 | 2019 | 15 | 0.610 |
Why?
| | Azepines | 4 | 2026 | 105 | 0.590 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 429 | 0.570 |
Why?
| | Metabolomics | 1 | 2024 | 737 | 0.570 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 933 | 0.550 |
Why?
| | Signal Transduction | 10 | 2024 | 5272 | 0.540 |
Why?
| | Proteomics | 1 | 2024 | 1205 | 0.520 |
Why?
| | Polycomb Repressive Complex 2 | 3 | 2015 | 79 | 0.510 |
Why?
| | Membrane Proteins | 4 | 2019 | 1171 | 0.510 |
Why?
| | Neoadjuvant Therapy | 1 | 2020 | 474 | 0.510 |
Why?
| | Pyridones | 2 | 2018 | 210 | 0.500 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 3 | 2026 | 55 | 0.500 |
Why?
| | Histones | 4 | 2026 | 672 | 0.490 |
Why?
| | Disease Progression | 10 | 2026 | 2892 | 0.490 |
Why?
| | Fatty Acids | 1 | 2020 | 461 | 0.490 |
Why?
| | Wnt Proteins | 2 | 2021 | 133 | 0.470 |
Why?
| | Biomarkers, Tumor | 6 | 2025 | 1339 | 0.470 |
Why?
| | Tumor Suppressor Protein p53 | 5 | 2026 | 536 | 0.460 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 6 | 2020 | 55 | 0.460 |
Why?
| | Cell Nucleus | 3 | 2025 | 589 | 0.460 |
Why?
| | Histone Deacetylases | 1 | 2017 | 208 | 0.460 |
Why?
| | DNA Breaks, Double-Stranded | 2 | 2026 | 55 | 0.440 |
Why?
| | B7-H1 Antigen | 3 | 2024 | 246 | 0.430 |
Why?
| | Methyltransferases | 1 | 2015 | 75 | 0.420 |
Why?
| | Cell Survival | 4 | 2026 | 1111 | 0.410 |
Why?
| | Protein Kinase Inhibitors | 2 | 2026 | 984 | 0.390 |
Why?
| | Molecular Targeted Therapy | 2 | 2021 | 444 | 0.390 |
Why?
| | Anoikis | 3 | 2023 | 31 | 0.390 |
Why?
| | Tryptophan | 2 | 2024 | 183 | 0.370 |
Why?
| | Peptides | 3 | 2023 | 1003 | 0.370 |
Why?
| | Biological Assay | 1 | 2013 | 134 | 0.370 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2015 | 440 | 0.370 |
Why?
| | Small Molecule Libraries | 1 | 2013 | 113 | 0.350 |
Why?
| | Gene Expression Profiling | 6 | 2023 | 1794 | 0.340 |
Why?
| | Triazoles | 3 | 2017 | 191 | 0.340 |
Why?
| | Carcinogenesis | 3 | 2024 | 230 | 0.330 |
Why?
| | Apoptosis | 6 | 2024 | 2454 | 0.310 |
Why?
| | Cells | 1 | 2010 | 25 | 0.310 |
Why?
| | Mice, Transgenic | 6 | 2024 | 2197 | 0.310 |
Why?
| | Inflammation | 2 | 2023 | 2921 | 0.300 |
Why?
| | Alternative Splicing | 2 | 2024 | 248 | 0.300 |
Why?
| | Neoplasm Invasiveness | 2 | 2024 | 512 | 0.300 |
Why?
| | Neoplasm Grading | 5 | 2024 | 313 | 0.300 |
Why?
| | Cisplatin | 3 | 2026 | 347 | 0.280 |
Why?
| | DNA End-Joining Repair | 2 | 2026 | 22 | 0.280 |
Why?
| | DNA Damage | 5 | 2026 | 440 | 0.280 |
Why?
| | Transcriptome | 3 | 2024 | 1059 | 0.280 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2025 | 1166 | 0.280 |
Why?
| | BRCA1 Protein | 3 | 2021 | 83 | 0.270 |
Why?
| | Carcinoma | 1 | 2010 | 231 | 0.270 |
Why?
| | Proto-Oncogene Proteins | 1 | 2011 | 627 | 0.270 |
Why?
| | RNA, Small Interfering | 5 | 2020 | 643 | 0.260 |
Why?
| | Piperidines | 2 | 2019 | 224 | 0.260 |
Why?
| | Fibroblasts | 1 | 2013 | 1040 | 0.260 |
Why?
| | Drug Synergism | 2 | 2025 | 355 | 0.250 |
Why?
| | E1A-Associated p300 Protein | 1 | 2026 | 15 | 0.240 |
Why?
| | Drug Delivery Systems | 1 | 2010 | 381 | 0.240 |
Why?
| | Receptors, Interleukin-8B | 1 | 2026 | 29 | 0.240 |
Why?
| | Ketoglutaric Acids | 1 | 2026 | 22 | 0.240 |
Why?
| | Aurora Kinase A | 1 | 2026 | 61 | 0.240 |
Why?
| | Peptide Fragments | 1 | 2010 | 698 | 0.240 |
Why?
| | Histone Deacetylase Inhibitors | 2 | 2018 | 219 | 0.230 |
Why?
| | Carnitine | 1 | 2026 | 91 | 0.230 |
Why?
| | Oncogenes | 2 | 2019 | 118 | 0.230 |
Why?
| | Imidazoles | 2 | 2024 | 247 | 0.220 |
Why?
| | Cell Cycle | 3 | 2025 | 600 | 0.220 |
Why?
| | Receptor, Interferon alpha-beta | 1 | 2024 | 35 | 0.210 |
Why?
| | Micronuclei, Chromosome-Defective | 1 | 2024 | 8 | 0.210 |
Why?
| | Prognosis | 3 | 2024 | 4384 | 0.210 |
Why?
| | Amino Acid Transport System ASC | 1 | 2024 | 12 | 0.210 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2024 | 56 | 0.210 |
Why?
| | Estrogen Receptor alpha | 1 | 2026 | 154 | 0.210 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2024 | 47 | 0.210 |
Why?
| | Ligands | 2 | 2024 | 675 | 0.200 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2024 | 224 | 0.200 |
Why?
| | Endogenous Retroviruses | 1 | 2024 | 37 | 0.200 |
Why?
| | DNA Transposable Elements | 1 | 2024 | 125 | 0.200 |
Why?
| | Wnt4 Protein | 2 | 2024 | 20 | 0.200 |
Why?
| | Repressor Proteins | 2 | 2018 | 429 | 0.200 |
Why?
| | Lysine | 2 | 2023 | 305 | 0.200 |
Why?
| | Aldehyde Dehydrogenase | 2 | 2016 | 99 | 0.200 |
Why?
| | Exons | 1 | 2024 | 365 | 0.200 |
Why?
| | Chromatin | 3 | 2025 | 561 | 0.190 |
Why?
| | Polycomb-Group Proteins | 1 | 2023 | 36 | 0.190 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 156 | 0.190 |
Why?
| | Kynurenine | 1 | 2024 | 114 | 0.190 |
Why?
| | Activating Transcription Factor 6 | 1 | 2023 | 19 | 0.190 |
Why?
| | Retinoblastoma-Binding Protein 2 | 1 | 2022 | 4 | 0.190 |
Why?
| | Cell Movement | 3 | 2018 | 966 | 0.180 |
Why?
| | Transcription Factor AP-1 | 1 | 2023 | 79 | 0.180 |
Why?
| | Pyrimidines | 1 | 2026 | 532 | 0.180 |
Why?
| | Indazoles | 2 | 2021 | 86 | 0.180 |
Why?
| | Cell Cycle Checkpoints | 4 | 2019 | 97 | 0.180 |
Why?
| | Down-Regulation | 4 | 2022 | 618 | 0.180 |
Why?
| | X-ray Repair Cross Complementing Protein 1 | 1 | 2022 | 14 | 0.180 |
Why?
| | Genital Neoplasms, Female | 1 | 2024 | 100 | 0.180 |
Why?
| | Acetylation | 2 | 2026 | 262 | 0.180 |
Why?
| | Tumor Cells, Cultured | 3 | 2019 | 891 | 0.180 |
Why?
| | Tripartite Motif-Containing Protein 28 | 1 | 2021 | 15 | 0.170 |
Why?
| | Carcinoma, Endometrioid | 1 | 2022 | 49 | 0.170 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2024 | 220 | 0.170 |
Why?
| | Granulosa Cells | 1 | 2021 | 37 | 0.170 |
Why?
| | Antigen Presentation | 1 | 2022 | 209 | 0.170 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 367 | 0.170 |
Why?
| | Killer Cells, Natural | 1 | 2024 | 481 | 0.170 |
Why?
| | RNA Interference | 3 | 2019 | 477 | 0.170 |
Why?
| | Transfection | 3 | 2021 | 930 | 0.170 |
Why?
| | Epigenomics | 1 | 2021 | 125 | 0.170 |
Why?
| | Promoter Regions, Genetic | 3 | 2017 | 1253 | 0.160 |
Why?
| | Ovarian Follicle | 1 | 2021 | 78 | 0.160 |
Why?
| | Proteins | 2 | 2017 | 1024 | 0.160 |
Why?
| | Gene Knockdown Techniques | 2 | 2020 | 334 | 0.160 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2021 | 87 | 0.160 |
Why?
| | Enzyme Inhibitors | 1 | 2024 | 822 | 0.160 |
Why?
| | Cell Culture Techniques | 2 | 2020 | 375 | 0.160 |
Why?
| | Macrophages | 3 | 2024 | 1530 | 0.160 |
Why?
| | Immunity | 2 | 2022 | 141 | 0.160 |
Why?
| | Lipids | 1 | 2025 | 723 | 0.150 |
Why?
| | Early Detection of Cancer | 1 | 2025 | 506 | 0.150 |
Why?
| | Wnt3A Protein | 1 | 2019 | 11 | 0.150 |
Why?
| | Germ-Line Mutation | 1 | 2021 | 180 | 0.150 |
Why?
| | Computational Biology | 1 | 2024 | 677 | 0.150 |
Why?
| | Neoplasm Transplantation | 2 | 2011 | 246 | 0.150 |
Why?
| | Interleukin-6 | 1 | 2024 | 784 | 0.150 |
Why?
| | Immunity, Innate | 2 | 2024 | 840 | 0.150 |
Why?
| | Immunotherapy | 2 | 2021 | 672 | 0.150 |
Why?
| | Transcription, Genetic | 4 | 2024 | 1456 | 0.150 |
Why?
| | Acyltransferases | 1 | 2019 | 78 | 0.150 |
Why?
| | Gene Frequency | 1 | 2021 | 498 | 0.150 |
Why?
| | Machine Learning | 1 | 2025 | 596 | 0.150 |
Why?
| | Receptors, Adiponectin | 1 | 2019 | 23 | 0.150 |
Why?
| | Diagnostic Imaging | 1 | 2022 | 342 | 0.150 |
Why?
| | Sequence Analysis, DNA | 2 | 2021 | 780 | 0.150 |
Why?
| | Amino Acid Sequence | 4 | 2015 | 2134 | 0.150 |
Why?
| | E2F Transcription Factors | 1 | 2019 | 65 | 0.150 |
Why?
| | NF-kappa B | 1 | 2023 | 676 | 0.140 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2023 | 794 | 0.140 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2019 | 72 | 0.140 |
Why?
| | CA-125 Antigen | 1 | 2018 | 13 | 0.140 |
Why?
| | Heterografts | 1 | 2019 | 143 | 0.140 |
Why?
| | Chloride Channels | 1 | 2018 | 33 | 0.140 |
Why?
| | Protein Processing, Post-Translational | 2 | 2021 | 482 | 0.140 |
Why?
| | Survival Rate | 2 | 2020 | 2110 | 0.140 |
Why?
| | RNA Splicing Factors | 1 | 2018 | 66 | 0.140 |
Why?
| | Drug Repositioning | 1 | 2018 | 40 | 0.130 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2018 | 130 | 0.130 |
Why?
| | Histone Deacetylase 6 | 1 | 2017 | 17 | 0.130 |
Why?
| | Mice, SCID | 3 | 2018 | 369 | 0.130 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2019 | 178 | 0.130 |
Why?
| | Genetic Testing | 1 | 2021 | 493 | 0.130 |
Why?
| | Paclitaxel | 1 | 2019 | 261 | 0.130 |
Why?
| | Cell Cycle Proteins | 4 | 2017 | 633 | 0.130 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1281 | 0.130 |
Why?
| | Claudins | 1 | 2017 | 23 | 0.130 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 443 | 0.130 |
Why?
| | HMGB2 Protein | 1 | 2016 | 4 | 0.120 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2020 | 268 | 0.120 |
Why?
| | Secretory Pathway | 1 | 2016 | 8 | 0.120 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2017 | 108 | 0.120 |
Why?
| | Mevalonic Acid | 1 | 2016 | 12 | 0.120 |
Why?
| | Adenocarcinoma, Clear Cell | 1 | 2016 | 14 | 0.120 |
Why?
| | Tight Junctions | 1 | 2017 | 87 | 0.120 |
Why?
| | Heterochromatin | 2 | 2016 | 68 | 0.120 |
Why?
| | Mass Spectrometry | 1 | 2019 | 728 | 0.120 |
Why?
| | RNA, Long Noncoding | 1 | 2018 | 173 | 0.120 |
Why?
| | Mammary Glands, Animal | 1 | 2017 | 128 | 0.120 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2017 | 269 | 0.120 |
Why?
| | Genetics, Population | 2 | 2008 | 226 | 0.120 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2019 | 459 | 0.120 |
Why?
| | Oxidation-Reduction | 1 | 2020 | 1077 | 0.120 |
Why?
| | Mice, Nude | 2 | 2015 | 680 | 0.120 |
Why?
| | Tumor Burden | 1 | 2017 | 327 | 0.120 |
Why?
| | Colorectal Neoplasms | 1 | 2024 | 877 | 0.120 |
Why?
| | Neoplasm Metastasis | 4 | 2026 | 695 | 0.110 |
Why?
| | Endopeptidases | 1 | 2015 | 80 | 0.110 |
Why?
| | Genetic Loci | 1 | 2016 | 272 | 0.110 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2017 | 383 | 0.110 |
Why?
| | Biomarkers | 2 | 2024 | 4354 | 0.110 |
Why?
| | Protein Binding | 3 | 2026 | 2249 | 0.110 |
Why?
| | Oxidative Stress | 1 | 2021 | 1368 | 0.100 |
Why?
| | Homologous Recombination | 2 | 2026 | 37 | 0.100 |
Why?
| | Disease Models, Animal | 2 | 2024 | 4605 | 0.100 |
Why?
| | T-Lymphocytes | 1 | 2022 | 2017 | 0.100 |
Why?
| | Epithelial Cells | 2 | 2017 | 1141 | 0.100 |
Why?
| | Oncogene Protein p21(ras) | 1 | 2013 | 15 | 0.100 |
Why?
| | Pyrimidine Nucleotides | 1 | 2013 | 3 | 0.100 |
Why?
| | Purine Nucleotides | 1 | 2013 | 12 | 0.100 |
Why?
| | beta-Galactosidase | 1 | 2013 | 76 | 0.100 |
Why?
| | CCAAT-Binding Factor | 1 | 2013 | 4 | 0.100 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 1195 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 2030 | 0.090 |
Why?
| | Tomography, X-Ray Computed | 1 | 2023 | 2791 | 0.090 |
Why?
| | Primary Cell Culture | 1 | 2013 | 173 | 0.090 |
Why?
| | Genes, Reporter | 1 | 2013 | 278 | 0.090 |
Why?
| | Aged, 80 and over | 2 | 2025 | 8432 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2012 | 76 | 0.090 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2017 | 915 | 0.090 |
Why?
| | Aged | 5 | 2025 | 26516 | 0.090 |
Why?
| | RNA Helicases | 1 | 2011 | 27 | 0.090 |
Why?
| | Mitosis | 2 | 2026 | 194 | 0.090 |
Why?
| | Genes, ras | 1 | 2011 | 96 | 0.090 |
Why?
| | Proteome | 1 | 2016 | 520 | 0.090 |
Why?
| | Wnt-5a Protein | 1 | 2011 | 25 | 0.090 |
Why?
| | Middle Aged | 6 | 2025 | 36821 | 0.080 |
Why?
| | Interferons | 2 | 2024 | 186 | 0.080 |
Why?
| | Molecular Sequence Data | 3 | 2015 | 2886 | 0.080 |
Why?
| | Golgi Apparatus | 1 | 2011 | 99 | 0.080 |
Why?
| | Gene Flow | 2 | 2008 | 91 | 0.080 |
Why?
| | Follow-Up Studies | 1 | 2020 | 5478 | 0.080 |
Why?
| | Cell Line | 4 | 2021 | 2832 | 0.080 |
Why?
| | AMP-Activated Protein Kinases | 2 | 2024 | 192 | 0.080 |
Why?
| | Models, Biological | 3 | 2019 | 1772 | 0.080 |
Why?
| | Endosomes | 1 | 2011 | 140 | 0.080 |
Why?
| | Gene Expression Regulation | 3 | 2016 | 2625 | 0.080 |
Why?
| | Cyclin D1 | 1 | 2010 | 64 | 0.080 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2010 | 117 | 0.080 |
Why?
| | Cloning, Molecular | 1 | 2010 | 539 | 0.070 |
Why?
| | Arachnida | 1 | 2008 | 5 | 0.070 |
Why?
| | Caenorhabditis elegans Proteins | 1 | 2011 | 209 | 0.070 |
Why?
| | Lung Neoplasms | 1 | 2022 | 2679 | 0.070 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2009 | 62 | 0.070 |
Why?
| | HEK293 Cells | 2 | 2024 | 745 | 0.070 |
Why?
| | Prostatic Neoplasms | 1 | 2015 | 986 | 0.070 |
Why?
| | Cytoplasm | 1 | 2009 | 255 | 0.070 |
Why?
| | Immunohistochemistry | 2 | 2022 | 1730 | 0.070 |
Why?
| | Trans-Activators | 1 | 2010 | 398 | 0.060 |
Why?
| | Transforming Growth Factor alpha | 1 | 2007 | 55 | 0.060 |
Why?
| | Mammary Neoplasms, Animal | 1 | 2007 | 35 | 0.060 |
Why?
| | Neoplasm Staging | 1 | 2011 | 1492 | 0.060 |
Why?
| | Bayes Theorem | 2 | 2026 | 428 | 0.060 |
Why?
| | Cactaceae | 1 | 2006 | 5 | 0.060 |
Why?
| | Triatoma | 1 | 2006 | 7 | 0.060 |
Why?
| | Acetyl Coenzyme A | 1 | 2026 | 8 | 0.060 |
Why?
| | Protein Structure, Tertiary | 1 | 2009 | 855 | 0.060 |
Why?
| | Mice, Inbred NOD | 2 | 2018 | 616 | 0.060 |
Why?
| | Mixed Function Oxygenases | 1 | 2026 | 43 | 0.060 |
Why?
| | Dioxygenases | 1 | 2026 | 36 | 0.060 |
Why?
| | Molecular Docking Simulation | 1 | 2026 | 119 | 0.060 |
Why?
| | Phylogeny | 2 | 2008 | 924 | 0.060 |
Why?
| | Phenylurea Compounds | 1 | 2026 | 122 | 0.060 |
Why?
| | Fructose | 1 | 2026 | 132 | 0.060 |
Why?
| | Acidosis | 1 | 2026 | 107 | 0.060 |
Why?
| | Maintenance Chemotherapy | 1 | 2025 | 42 | 0.060 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2026 | 77 | 0.060 |
Why?
| | Drosophila | 1 | 2006 | 168 | 0.060 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2026 | 536 | 0.050 |
Why?
| | Genetic Variation | 2 | 2008 | 995 | 0.050 |
Why?
| | Evolution, Molecular | 1 | 2008 | 502 | 0.050 |
Why?
| | Epigenesis, Genetic | 2 | 2020 | 708 | 0.050 |
Why?
| | Retinal Dehydrogenase | 2 | 2016 | 29 | 0.050 |
Why?
| | Protein Transport | 2 | 2019 | 442 | 0.050 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2026 | 196 | 0.050 |
Why?
| | Carbonyl Reductase (NADPH) | 1 | 2024 | 5 | 0.050 |
Why?
| | Mutation, Missense | 1 | 2026 | 337 | 0.050 |
Why?
| | Signal-To-Noise Ratio | 1 | 2023 | 73 | 0.050 |
Why?
| | Transcription Factor RelB | 1 | 2023 | 3 | 0.050 |
Why?
| | Cytokine TWEAK | 1 | 2023 | 2 | 0.050 |
Why?
| | Protein Isoforms | 1 | 2024 | 398 | 0.050 |
Why?
| | Tumor Necrosis Factors | 1 | 2023 | 10 | 0.050 |
Why?
| | TWEAK Receptor | 1 | 2023 | 6 | 0.050 |
Why?
| | Enhancer Elements, Genetic | 1 | 2024 | 191 | 0.050 |
Why?
| | Muscular Atrophy | 1 | 2023 | 87 | 0.050 |
Why?
| | Artifacts | 1 | 2023 | 144 | 0.050 |
Why?
| | Cachexia | 1 | 2023 | 74 | 0.050 |
Why?
| | Recombinational DNA Repair | 1 | 2022 | 19 | 0.050 |
Why?
| | Carboplatin | 1 | 2023 | 168 | 0.050 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2023 | 163 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2016 | 751 | 0.040 |
Why?
| | Estradiol | 1 | 2026 | 515 | 0.040 |
Why?
| | Gene Regulatory Networks | 1 | 2024 | 318 | 0.040 |
Why?
| | Eukaryotic Initiation Factor-2 | 1 | 2021 | 32 | 0.040 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2021 | 44 | 0.040 |
Why?
| | Open Reading Frames | 1 | 2021 | 130 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2022 | 502 | 0.040 |
Why?
| | Neutrophils | 1 | 2026 | 1135 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2025 | 2080 | 0.040 |
Why?
| | Cell Division | 1 | 2021 | 758 | 0.040 |
Why?
| | Culture Media, Conditioned | 1 | 2019 | 112 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 347 | 0.040 |
Why?
| | Paracrine Communication | 1 | 2019 | 67 | 0.040 |
Why?
| | Mice, Inbred C57BL | 3 | 2018 | 6042 | 0.040 |
Why?
| | Chromatin Assembly and Disassembly | 1 | 2020 | 109 | 0.040 |
Why?
| | Coculture Techniques | 1 | 2019 | 247 | 0.040 |
Why?
| | Blotting, Western | 2 | 2011 | 1186 | 0.040 |
Why?
| | Computer Simulation | 1 | 2023 | 1018 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2020 | 325 | 0.040 |
Why?
| | DNA | 1 | 2025 | 1444 | 0.030 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2019 | 138 | 0.030 |
Why?
| | Protein Biosynthesis | 1 | 2021 | 452 | 0.030 |
Why?
| | Gene Amplification | 1 | 2018 | 118 | 0.030 |
Why?
| | Stem Cells | 1 | 2023 | 630 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2022 | 1172 | 0.030 |
Why?
| | Survival Analysis | 1 | 2021 | 1386 | 0.030 |
Why?
| | Desert Climate | 2 | 2008 | 15 | 0.030 |
Why?
| | Aniline Compounds | 1 | 2018 | 120 | 0.030 |
Why?
| | Recurrence | 1 | 2021 | 1151 | 0.030 |
Why?
| | Arizona | 2 | 2008 | 81 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2025 | 3660 | 0.030 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2019 | 232 | 0.030 |
Why?
| | DNA Helicases | 1 | 2018 | 137 | 0.030 |
Why?
| | Mexico | 2 | 2008 | 233 | 0.030 |
Why?
| | Phosphorylation | 1 | 2021 | 1721 | 0.030 |
Why?
| | Disease Management | 1 | 2021 | 654 | 0.030 |
Why?
| | Pyridines | 1 | 2021 | 610 | 0.030 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2018 | 222 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2021 | 1225 | 0.030 |
Why?
| | DNA, Mitochondrial | 2 | 2008 | 212 | 0.030 |
Why?
| | Gene Knockout Techniques | 1 | 2016 | 122 | 0.030 |
Why?
| | Sumoylation | 1 | 2015 | 17 | 0.030 |
Why?
| | Lactation | 1 | 2017 | 195 | 0.030 |
Why?
| | Metabolic Networks and Pathways | 1 | 2016 | 175 | 0.030 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2016 | 180 | 0.030 |
Why?
| | Algorithms | 1 | 2023 | 1868 | 0.030 |
Why?
| | Models, Genetic | 2 | 2008 | 536 | 0.030 |
Why?
| | Proteolysis | 1 | 2015 | 173 | 0.030 |
Why?
| | Gene Silencing | 1 | 2015 | 203 | 0.030 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2017 | 432 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2016 | 453 | 0.030 |
Why?
| | Sulfonamides | 1 | 2018 | 596 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2017 | 1266 | 0.030 |
Why?
| | E2F7 Transcription Factor | 1 | 2013 | 1 | 0.020 |
Why?
| | Ribonucleoside Diphosphate Reductase | 1 | 2013 | 6 | 0.020 |
Why?
| | Melanoma | 1 | 2020 | 774 | 0.020 |
Why?
| | Nucleosides | 1 | 2013 | 25 | 0.020 |
Why?
| | Muscle, Skeletal | 1 | 2023 | 1798 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2016 | 575 | 0.020 |
Why?
| | Cell Growth Processes | 1 | 2013 | 48 | 0.020 |
Why?
| | Epidermal Growth Factor | 1 | 2012 | 162 | 0.020 |
Why?
| | ras Proteins | 1 | 2013 | 153 | 0.020 |
Why?
| | Fanconi Anemia Complementation Group Proteins | 1 | 2011 | 7 | 0.020 |
Why?
| | Adult | 2 | 2025 | 41406 | 0.020 |
Why?
| | Genes, BRCA1 | 1 | 2011 | 45 | 0.020 |
Why?
| | Sorting Nexins | 1 | 2011 | 12 | 0.020 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2011 | 139 | 0.020 |
Why?
| | Two-Hybrid System Techniques | 1 | 2011 | 59 | 0.020 |
Why?
| | Time Factors | 2 | 2016 | 7173 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2018 | 3153 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2011 | 149 | 0.020 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2013 | 230 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2011 | 337 | 0.020 |
Why?
| | Endocytosis | 1 | 2011 | 168 | 0.020 |
Why?
| | Protein Folding | 1 | 2011 | 280 | 0.020 |
Why?
| | HeLa Cells | 1 | 2011 | 633 | 0.020 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2011 | 340 | 0.020 |
Why?
| | Recombinant Fusion Proteins | 1 | 2011 | 669 | 0.020 |
Why?
| | Geography | 1 | 2008 | 187 | 0.020 |
Why?
| | Phenotype | 1 | 2016 | 3216 | 0.020 |
Why?
| | Population Dynamics | 1 | 2008 | 143 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2015 | 4170 | 0.020 |
Why?
| | Caenorhabditis elegans | 1 | 2011 | 330 | 0.020 |
Why?
| | Genes, Insect | 1 | 2006 | 22 | 0.020 |
Why?
| | Haplotypes | 1 | 2008 | 509 | 0.020 |
Why?
| | Cytochromes b | 1 | 2006 | 12 | 0.020 |
Why?
| | Electron Transport Complex IV | 1 | 2006 | 61 | 0.010 |
Why?
| | Insect Vectors | 1 | 2006 | 39 | 0.010 |
Why?
| | Chagas Disease | 1 | 2006 | 42 | 0.010 |
Why?
| | Host-Parasite Interactions | 1 | 2006 | 110 | 0.010 |
Why?
| | Lymphoma | 1 | 2007 | 253 | 0.010 |
Why?
| | Pregnancy | 1 | 2017 | 7276 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2011 | 2812 | 0.010 |
Why?
| | Firefly Luciferin | 1 | 1957 | 1 | 0.010 |
Why?
| | Diptera | 1 | 1957 | 31 | 0.010 |
Why?
| | Luciferases | 1 | 1957 | 155 | 0.010 |
Why?
| | Male | 1 | 2015 | 73954 | 0.000 |
Why?
|
|
Bitler's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|